Communiqués Aclarion, Inc.

Actions

ACON

US6551874091

Recherche biotechnologique et médicale

Temps Différé Nasdaq 19:03:35 23/09/2026			Varia. 5j.	Varia. 1 janv.
2,610 ^USD	-0,76%		+2,35%	-43,26%

20/08	Aclarion intègre la faculté de médecine de l'Université de l'Arizona à Phoenix comme site d'étude pour l'essai CLARITY	CI
12/08	Aclarion reçoit un avis d'acceptation de brevet renforçant la précision et l'adoption du processus d'imagerie par spectroscopie RM Nociscan	CI

Communiqués

20/08	Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site	AQ
12/08	Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process	AQ
04/08	Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology	AQ
29/07	Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026	AQ
21/07	Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical Practice	AQ
07/07	Aclarion Announces Texas Spine Care Center as New CLARITY Site	AQ
10/06	Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub	AQ
09/06	Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform	AQ
08/06	Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal	AQ
08/06	Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting	AQ
03/06	Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation	AQ
01/06	Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study	AQ
28/05	Aclarion, Inc. Comments on Echo Lake Capital’s Letter and Unsolicited Proposal	AQ
28/05	Echo Lake Capital Offers To Acquire Aclarion Inc.	AQ
07/05	Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment	AQ
06/05	Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.	AQ
05/05	Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine	AQ
30/04	Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption	AQ
28/04	Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan	AQ
22/04	Aclarion Announces $2.5 Million Stock Repurchase Plan	AQ
16/04	Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain	AQ
14/04	Aclarion Receives Pinnacle Award for AI Innovation	AQ
08/04	Aclarion Announces Agreement with Weill Cornell Medicine	AQ
07/04	Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video	AQ
24/03	Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc.	AQ